



Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum

March 12, 2026

BURLINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in The Stifel 2026 Virtual CNS Forum being held March 17-18, 2026.

The Stifel 2026 Virtual CNS Forum

Format: Company presentation

Day/Time: Wednesday, March 18 at 8.30 AM ET

Webcast: **Webcast Link:**

<https://event.summitcast.com/view/4Ggc9Rmi4GQpDPGZwDp8g8/DdYPDYFQLLU6kp2AWRS6bu>

If you are interested in a virtual meeting with the Minerva team during the conference, please reach out to your Stifel representative.

A replay of the presentation will be available on the Company's Investors & Media [Events and Presentations](#) webpage for ninety days following the event.

About Minerva Neurosciences

Minerva **Neurosciences, Inc.** is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva is initiating a confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia. For more information, please visit the Company's [website](#).

Contacts:

Investor inquiries:

Frederick Ahlholm

Chief Financial Officer

Minerva Neurosciences, Inc.

FAhlholm@minervaneurosciences.com

Corey Davis, Ph.D.

LifeSci Advisors, LLC

212-915-2577

cdavis@lifesciadvisors.com